Should patients with high-risk localised or locally advanced prostate cancer receive abiraterone acetate in addition to androgen deprivation therapy? update on a planned analysis of the STAMPEDE Trial
AffiliationUniversity College London Cancer Institute, London, UK.
MetadataShow full item record
CitationAttard G, Brown LC, Clarke NW, Parmar MKB, James ND. Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. European Urology. 2021 Jul.